WuXi STA – a subsidiary of WuXi AppTec – today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland from Bristol Myers Squibb (NYSE: BMY). WuXi STA first announced its plans to purchase the facility earlier this year. The acquisition will enhance WuXi STA’s capabilities by adding capacity to support its global partners in bringing innovative medicines to patients around the world.
The Couvet site is the first facility in Europe for WuXi STA. Opened in 2018, this facility’s state-of-the-art tablet & capsule manufacturing and packaging capabilities will provide WuXi STA’s customers more flexibility thanks to an enhanced supply of global drug product and greater access to the European market and beyond.
By enhancing its network, WuXi STA can better support customers’ long-term needs globally, as they bring new and existing commercial manufacturing projects from their pipelines to the facility, with the capability and capacity to supply drug products to major global markets.
“We are delighted to have added the Couvet site to our global supply network and are excited to welcome its highly skilled team to the WuXi STA family,” said Dr. Minzhang Chen, Co-CEO of WuXi AppTec. “Through combining resources of the Couvet site with our other facilities, we continue strengthening and broadening our capacity and capabilities to better support our global customers in delivering innovative medicines to patients in need.”
Through this transaction, WuXi STA has increased its global presence to eight R&D and manufacturing sites across Asia, North America and Europe, including the recently announced Middletown site in Delaware, USA.
